Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06788964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

Study acronym: CORAL
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 4 of 4 entries Study sites: 1 to 2 · Eligibility criteria expanded, about 60 words · Secondary endpoints: details revised at 1 of 9 entries Show 3 more changesShow less
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 60 words
    • Secondary endpoints: details revised at 1 of 9 entries
  2. Eligibility criteria expanded, about 9 wordsv7 See this version in full on ClinicalTrials.gov ↗
  3. Start date: Jul 1, 2025 to Aug 25, 2025 Site contact updated · Study title shortened, about 2 wordsv6 Show 2 more changesShow less
    • Site contact updated
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Primary endpoints revised (4) · Start date changed from estimate of Jun 2025 to Jul 1, 2025 · Site details revisedv5 Show 3 more changesShow less
    • Primary endpoints revised (4)
    • Start date changed from estimate of Jun 2025 to Jul 1, 2025
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  5. Start date: Apr 2025 to Jun 2025v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Mar 2025 to Apr 2025v3
  2. Primary endpoints: 2 to 4 Interventions: Loncastuximab Tesirine and Rituximab (Drug) to Loncastuximab Tesirine (Drug), Rituximab (Drug) · Secondary endpoints: 6 to 9v2 Show 2 more changesShow less
    • Interventions: Loncastuximab Tesirine and Rituximab (Drug) to Loncastuximab Tesirine (Drug), Rituximab (Drug)
    • Secondary endpoints: 6 to 9

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Utah
302 trials monitored
See 17 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
DLBCL
650 trials monitored
See 38 trials at risk
The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory large B-cell lymphoma.
Trial Details
NCT Number NCT06788964
Lead Sponsor University of Utah
Collaborators: ADC Therapeutics S.A.
Conditions Relapsed or Refractory Large B-cell Lymphoma
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov